SAB Biotherapeutics, Inc. (SABS) SEC filings

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30

$2.96−0.12 (-3.90%)

Close on Nov 13, 2026Market cap $269.32MP/E –Yield –

SEC filings

40 of SAB Biotherapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 13, 2026	Oct 13, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jul 7, 2026	Jul 7, 2026	SEC EDGAR
Current report	8-K	Jun 18, 2026	Jun 18, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	Apr 28, 2026	May 4, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 18, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 22, 2026	Apr 22, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 19, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 9, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Jan 5, 2026	Jan 7, 2026	SEC EDGAR
Current report	8-K	Dec 29, 2025	Dec 29, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 14, 2025	SEC EDGAR
Current report	8-K	Sep 30, 2025	Sep 30, 2025	SEC EDGAR
Current report	8-K	Sep 26, 2025	Sep 26, 2025	SEC EDGAR
Proxy statement	DEF 14A	Sep 26, 2025	Aug 29, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jul 21, 2025	Jul 21, 2025	SEC EDGAR
Current report	8-K	Jul 17, 2025	Jul 17, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jul 17, 2025	Jun 2, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 9, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 31, 2025	SEC EDGAR
Current report	8-K	Jan 30, 2025	Feb 5, 2025	SEC EDGAR
Current report	8-K	Jan 28, 2025	Jan 28, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Sep 9, 2024	Sep 9, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jul 26, 2024	Jul 31, 2024	SEC EDGAR
Current report	8-K	Jun 27, 2024	Jun 27, 2024	SEC EDGAR
Current report	8-K	May 26, 2024	May 31, 2024	SEC EDGAR
Proxy statement	DEF 14A	May 22, 2024	May 30, 2024	SEC EDGAR
Current report	8-K	May 21, 2024	May 21, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 20, 2024	SEC EDGAR
Current report	8-K	May 3, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	Apr 12, 2024	Apr 15, 2024	SEC EDGAR
Current report	8-K	Mar 29, 2024	Mar 29, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Mar 29, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in SAB Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5.67 reverse split on Mar 29, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SABS.

Compare: SABS vs SCNI · SABS vs IMA · SABS vs PLUR · SABS vs INBX · SABS vs PROK

Revenue growth-100.0% · median 7.1%

Company	Revenue	Growth
PLUR	$1.46M	+10.0%
PROK	$775.00K	+4.2%
SABS	$0	-100.0%
SCNI	–	–
IMA	–	–
INBX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 86
Held by institutions: 75.2%
Auditor: EisnerAmper L.L.P.
SEC CIK: 1833214

Advertisement
300 × 250

See a number that looks wrong?